Trevi Therapeutics, Inc.
General ticker "TRVI" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $735.5M (TTM average)
Trevi Therapeutics, Inc. follows the US Stock Market performance with the rate: 39.8%.
Estimated limits based on current volatility of 3.8%: low 13.25$, high 14.29$
Factors to consider:
- Total employees count: 26 (+4.0%) as of 2024
- Top business risk factors: Operational and conduct risks, Single product reliance, Regulatory and compliance, Labor/talent shortage/retention, Transition to commercialization
- Current price 128.8% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [2.34$, 5.89$]
- 2025-12-31 to 2026-12-31 estimated range: [1.94$, 5.03$]
Financial Metrics affecting the TRVI estimates:
- Positive: with PPE of -8.8 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -9.18 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Positive: Shareholder equity ratio, % of 89.85 > 63.39
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: Industry earnings per price (median), % of -16.34 <= 0
- Positive: Interest expense per share per price, % of 0 <= 0.01
Short-term TRVI quotes
Long-term TRVI plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $29.91MM | $33.92MM | $51.52MM |
| Operating Income | $-29.91MM | $-33.92MM | $-51.52MM |
| Non-Operating Income | $0.72MM | $4.83MM | $3.58MM |
| Interest Expense | $1.16MM | $0.39MM | $0.00MM |
| R&D Expense | $19.83MM | $23.68MM | $39.38MM |
| Income(Loss) | $-29.19MM | $-29.10MM | $-47.94MM |
| Taxes | $-0.04MM | $-0.03MM | $-0.03MM |
| Profit(Loss)* | $-29.15MM | $-29.07MM | $-47.91MM |
| Stockholders Equity | $107.46MM | $82.55MM | $99.64MM |
| Assets | $123.02MM | $89.40MM | $110.90MM |
| Operating Cash Flow | $-28.18MM | $-31.71MM | $-38.26MM |
| Capital expenditure | $0.16MM | $0.14MM | $0.04MM |
| Investing Cash Flow | $-107.37MM | $59.43MM | $-21.53MM |
| Financing Cash Flow | $111.31MM | $-7.91MM | $61.48MM |
| Earnings Per Share** | $-0.45 | $-0.29 | $-0.47 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.